Literature DB >> 28443237

The clinical heterogeneity of late-onset MELAS.

H K Atwal1, J Gass2, P R Blackburn2, P S Atwal2.   

Abstract

Entities:  

Keywords:  Gene; MELAS; Mitochondrial disorder; Stroke-like episode; m.3243A > G; mtDNA

Year:  2017        PMID: 28443237      PMCID: PMC5394211          DOI: 10.1016/j.ymgmr.2017.04.003

Source DB:  PubMed          Journal:  Mol Genet Metab Rep        ISSN: 2214-4269


× No keyword cloud information.
We read with interest the response by Finsterer and Zarrouk-Mahjoub [1] to our manuscript ‘Case Report: 5 Year Follow-up of Adult Late-Onset Mitochondrial Encephalomyopathy with Lactic Acid and Stroke-Like Episodes (MELAS)’ [2], [3], [4]. We have the following responses: Regarding the doses of initial anti-epileptic medication (AEDs), since this was some time ago and at a different institution we do not have accurate dosing. Currently, however, the patient is on levetiracetam 2000 mg BID and lamotrigine 250 mg BID. Initially she required multiple AEDs due to poor control. Phenytoin was given initially as the diagnosis of MELAS was not established at that time. Her seizures appeared independent of her stroke-like episodes (SLEs). Her transient episodes of confusion were attributable to her stroke-like episodes and not AEDs, they resolved without change in AED dosing. The authors are correct that clonazepam (not clonazapan) was one of the AEDs used. Heteroplasmy rates were not determined in other tissues as the diagnosis was clear due to her clinical presentation coupled with the molecular findings. It is possible, and indeed likely, that heteroplasmy rates differed in other tissues but it was felt not necessary to test them; additionally heteroplasmy rates were not measured over time as this would not have changed her clinical management. The patient did have a brain MRI (or cMRI as the author states) during a SLE which showed multiple areas of cortical signal intensity involving both the cortex and subcortical U-fibers. Additionally there was cortical and subcortical involvement involving the posterior aspects of both temporal lobes; given this extent of involvement these changes were felt to be consistent with MELAS. Lastly, there was gyral and dural enhancement overlying the areas of abnormal signal intensity in multiple areas. The patient's mother was not available for testing but family history for hearing loss was significant in the proband's mother, older brother, and maternal aunt, but none of these relatives have experienced seizures or stroke-like episodes. Both of the patient's grandmothers died of strokes in their 70s–80s, the etiology of which is unclear. Once again we thank Finsterer and Zarrouk-Mahjoub for their interest in this case and appreciate their comments and hope we have been able to answer them in a satisfactory manner.
  4 in total

1.  Onset of MELAS due to the m.3243A > G mutation is early if the large phenotypic variability is considered.

Authors:  Josef Finsterer; Sinda Zarrouk-Mahjoub
Journal:  Mol Genet Metab Rep       Date:  2016-12-12

2.  Case report: 5 year follow-up of adult late-onset mitochondrial encephalomyopathy with lactic acid and stroke-like episodes (MELAS).

Authors:  Kiri Sunde; Patrick R Blackburn; Anvir Cheema; Jennifer Gass; Jessica Jackson; Sarah Macklin; Paldeep S Atwal
Journal:  Mol Genet Metab Rep       Date:  2016-11-18

3.  Late-onset mitochondrial encephalomyopathy with lactic acid and stroke-like episodes (MELAS), defining symptomology.

Authors:  J Gass; H K Atwal; P S Atwal
Journal:  Mol Genet Metab Rep       Date:  2017-01-11

4.  Low blood heteroplasmy-rate may cause late-onset MELAS.

Authors:  Josef Finsterer; Sinda Zarrouk-Mahjoub
Journal:  Mol Genet Metab Rep       Date:  2017-02-04
  4 in total
  1 in total

1.  Mitochondrial Disease (MELAS Syndrome) Discovered at the Start of Pregnancy in a Patient with Advanced CKD: A Clinical and Ethical Challenge.

Authors:  Domenico Santoro; Gianluca Di Bella; Antonio Toscano; Olimpia Musumeci; Michele Buemi; Giorgina Barbara Piccoli
Journal:  J Clin Med       Date:  2019-03-04       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.